Francesco Passamonti

Jan 26, 2025 | tandfonline.com | Francesco Passamonti |Siddhi Korgaonkar |Rohan Parikh |Manoj Chevli

ABSTRACTAim Assess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX). Patients & Methods This study was a retrospective, noninterventional medical record review of patients in Canada, Germany, and the United Kingdom (UK). A total of 70 physicians (primarily hematologist-oncologists [78.6%]) provided data for 196 eligible patients.

Mar 1, 2024 | corriere.it | Francesco Passamonti

La terapia dipende dai sintomi e oggi è possibile allungare la sopravvivenza dei malati e ridurre i disturbi debilitanti permettendo, nella maggior parte dei casi, il ritorno alle attività quotidiane e lavorative e a una normale vita sociale Ho 45 anni e quattro anni fa ho scoperto di avere la mielofibrosi, che per ora non necessita di terapie, ma so che potrebbe evolvere in una leucemia acuta.

Aug 17, 2023 | onlinelibrary.wiley.com | Michele Merli |Francesco Passamonti |Luca Arcaini

Hepatitis C virus (HCV) virus has been associated with a wide spectrum of lymphoproliferative disorders (LPD), ranging from mixed cryoglobulinemia (MC) to overt B-cell lymphomas, especially indolent subtypes, mostly represented by marginal-zone lymphomas (MZL), and diffuse large B-cell lymphomas.1 The most compelling evidence supporting the aetiological role of HCV in sustaining B-cell lymphoproliferation is represented by clinical studies reporting the regression of indolent LPD after HCV...

Jul 28, 2023 | nature.com | Alessandra Carobbio |Elisa Rumi |Valerio De Stefano |Alessandro Rambaldi |Francesco Passamonti |Naseema Gangat | +1 more

Dear EditorAmple evidence has been provided that accurate discrimination between essential thrombocythemia (ET) and early prefibrotic primary myelofibrosis (pre-PMF) has an impact not only on presenting laboratory data but also on complications, like thrombosis, progression to overt myelofibrosis (MF), transformation to blast phase (BP), and overall survival [1,2,3,4,5,6,7,8].